1 Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395, 497-506, doi:10.1016/s0140-6736(20)30183-5 (2020).
2 Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395, 507-513, doi:10.1016/s0140-6736(20)30211-7 (2020).
3 Luo, L. et al. The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis. Clin Cardiol 43, 1478-1493, doi:10.1002/clc.23465 (2020).
4 Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases 20, 533-534, doi:10.1016/s1473-3099(20)30120-1 (2020).
5 Kamboj, M. & Sepkowitz, K. A. Nosocomial infections in patients with cancer. Lancet Oncol 10, 589-597, doi:10.1016/S1470-2045(09)70069-5 (2009).
6 Li, J. Y. et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res 2014, 286170, doi:10.1155/2014/286170 (2014).
7 Longbottom, E. R. et al. Features of Postoperative Immune Suppression Are Reversible With Interferon Gamma and Independent of Interleukin-6 Pathways. Ann Surg 264, 370-377, doi:10.1097/SLA.0000000000001484 (2016).
8 Sica, A. & Massarotti, M. Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun 85, 117-125, doi:10.1016/j.jaut.2017.07.010 (2017).
9 Schmidt, T. et al. Influence of physical activity on the immune system in breast cancer patients during chemotherapy. J Cancer Res Clin Oncol 144, 579-586, doi:10.1007/s00432-017-2573-5 (2018).
10 Hodgson, S. H. et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The Lancet Infectious Diseases 21, e26-e35, doi:10.1016/s1473-3099(20)30773-8 (2021).
11 Callaway, E. The race for coronavirus vaccines: a graphical guide. Nature 580, 576-577, doi:10.1038/d41586-020-01221-y (2020).
12 Lazarus, J. V. et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 27, 225-228, doi:10.1038/s41591-020-1124-9 (2021).
13 Wang, J. et al. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. Vaccines (Basel) 8, doi:10.3390/vaccines8030482 (2020).
14 Zhang, Y., Luo, X. & Ma, Z. F. Willingness of the general population to accept and pay for COVID-19 vaccination during the early stages of COVID-19 pandemic: a nationally representative survey in mainland China. Hum Vaccin Immunother 17, 1622-1627, doi:10.1080/21645515.2020.1847585 (2021).
15 Barriere, J. et al. Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey. Ann Oncol 32, 673-674, doi:10.1016/j.annonc.2021.01.066 (2021).
16 Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71, 209-249, doi:10.3322/caac.21660 (2021).
17 Matsen, C. B. & Neumayer, L. A. Breast cancer: a review for the general surgeon. JAMA Surg 148, 971-979, doi:10.1001/jamasurg.2013.3393 (2013).
18 Allemani, C. et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet 391, 1023-1075, doi:10.1016/s0140-6736(17)33326-3 (2018).
19 Desai, A., Sachdeva, S., Parekh, T. & Desai, R. COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis. JCO Glob Oncol 6, 557-559, doi:10.1200/GO.20.00097 (2020).
20 Liang, W. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21, 335-337, doi:10.1016/S1470-2045(20)30096-6 (2020).
21 Gasparri, M. L. et al. Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST). Breast 52, 110-115, doi:10.1016/j.breast.2020.05.006 (2020).
22 Dietz, J. R. et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat 181, 487-497, doi:10.1007/s10549-020-05644-z (2020).
23 Izcovich, A. et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One 15, e0241955, doi:10.1371/journal.pone.0241955 (2020).
24 Ribas, A. et al. Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discov 11, 233-236, doi:10.1158/2159-8290.CD-20-1817 (2021).
25 Noor, F. M. & Islam, M. M. Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis. J Community Health 45, 1270-1282, doi:10.1007/s10900-020-00920-x (2020).
26 Rubin, L. G. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58, e44-100, doi:10.1093/cid/cit684 (2014).
27 Carreira, H. et al. Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review. J Natl Cancer Inst 110, 1311-1327, doi:10.1093/jnci/djy177 (2018).
28 Maass, S. W., Roorda, C., Berendsen, A. J., Verhaak, P. F. & de Bock, G. H. The prevalence of long-term symptoms of depression and anxiety after breast cancer treatment: A systematic review. Maturitas 82, 100-108, doi:10.1016/j.maturitas.2015.04.010 (2015).
29 Carreira, H., Williams, R., Funston, G., Stanway, S. & Bhaskaran, K. Associations between breast cancer survivorship and adverse mental health outcomes: A matched population-based cohort study in the United Kingdom. PLoS Med 18, e1003504, doi:10.1371/journal.pmed.1003504 (2021).
30 Anderson, E. J. et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med 383, 2427-2438, doi:10.1056/NEJMoa2028436 (2020).
31 Hwang, J. K., Zhang, T., Wang, A. Z. & Li, Z. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. J Hematol Oncol 14, 38, doi:10.1186/s13045-021-01046-w (2021).
32 So, A. C. P. et al. COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers (Basel) 13, doi:10.3390/cancers13143573 (2021).
33 McDonald, I., Murray, S. M., Reynolds, C. J., Altmann, D. M. & Boyton, R. J. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines 6, 74, doi:10.1038/s41541-021-00336-1 (2021).
34 Liu, Z. W. et al. PHQ-9 and PHQ-2 for Screening Depression in Chinese Rural Elderly. PLoS One 11, e0151042, doi:10.1371/journal.pone.0151042 (2016).
35 Plummer, F., Manea, L., Trepel, D. & McMillan, D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry 39, 24-31, doi:10.1016/j.genhosppsych.2015.11.005 (2016).